Hertel Oliver, Neuss Anne, Busche Tobias, Brandt David, Kalinowski Jörn, Bahnemann Janina, Noll Thomas
Cell Culture Technology, Faculty of Technology, Bielefeld University, Bielefeld, Germany.
Center for Biotechnology (CeBiTec), Bielefeld University, Bielefeld, Germany.
Front Bioeng Biotechnol. 2022 Oct 13;10:1010719. doi: 10.3389/fbioe.2022.1010719. eCollection 2022.
Chinese hamster ovary (CHO) cells are the most important platform for producing biotherapeutics. Random integration of a transgene into epigenetically instable regions of the genome results in silencing of the gene of interest and loss of productivity during upstream processing. Therefore, cost- and time-intensive long-term stability studies must be performed. Site-specific integration into safe harbors is a strategy to overcome these limitations of conventional cell line design. Recent publications predict safe harbors in CHO cells based on omics data sets or by learning from random integrations, but those predictions remain theory. In this study, we established a CRISPR/Cas9-mediated site-specific integration strategy based on ChIP-seq data to improve stability of recombinant CHO cells. Therefore, a ChIP experiment from the exponential and stationary growth phase of a fed-batch cultivation of CHO-K1 cells yielded 709 potentially stable integration sites. The reporter gene eGFP was integrated into three regions harboring specific modifications by CRISPR/Cas9. Targeted Cas9 nanopore sequencing showed site-specific integration in all 3 cell pools with a specificity between 23 and 73%. Subsequently, the cells with the three different integration sites were compared with the randomly integrated donor vector in terms of transcript level, productivity, gene copy numbers and stability. All site-specific integrations showed an increase in productivity and transcript levels of up to 7.4-fold. In a long-term cultivation over 70 generations, two of the site-specific integrations showed a stable productivity (>70%) independent of selection pressure.
中国仓鼠卵巢(CHO)细胞是生产生物治疗药物最重要的平台。转基因随机整合到基因组中表观遗传不稳定区域会导致目的基因沉默,并在上游加工过程中丧失生产力。因此,必须进行成本高且耗时的长期稳定性研究。定点整合到安全位点是克服传统细胞系设计这些局限性的一种策略。最近的出版物基于组学数据集或通过从随机整合中学习来预测CHO细胞中的安全位点,但这些预测仍停留在理论层面。在本研究中,我们基于染色质免疫沉淀测序(ChIP-seq)数据建立了一种CRISPR/Cas9介导的定点整合策略,以提高重组CHO细胞的稳定性。因此,对CHO-K1细胞补料分批培养的指数生长期和稳定期进行的ChIP实验产生了709个潜在的稳定整合位点。通过CRISPR/Cas9将报告基因eGFP整合到三个具有特定修饰的区域。靶向Cas9纳米孔测序显示在所有3个细胞库中均发生了定点整合,特异性在23%至73%之间。随后,将具有三种不同整合位点的细胞与随机整合的供体载体在转录水平、生产力、基因拷贝数和稳定性方面进行了比较。所有定点整合均显示生产力和转录水平提高了7.4倍。在超过70代的长期培养中,其中两个定点整合显示出稳定的生产力(>70%),且与选择压力无关。